Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Succinate promotes multiple myeloma cell proliferation through TCA cycle oxidation.

Created on 07 Nov 2026

Authors

Nancy Gudgeon, Taylor Fulton-Ward, Victoria Stavrou, Aidan Haslam, Graham McIlroy, Hannah Giles, Guy Pratt, Sarah Dimeloe

Published in

Cell reports. Volume 45. Issue 11. Pages 118267. Nov 06, 2026. Epub Nov 06, 2026.

Abstract

Multiple myeloma is a plasma cell malignancy that develops within the bone marrow. The bone marrow metabolome is altered in myeloma, with implications for malignant cell growth. Here, the impact of elevated bone marrow levels of the tricarboxylic acid (TCA) cycle metabolite, succinate, was interrogated. Succinate was found to promote proliferation of several myeloma cell lines. This was linked to its uptake and oxidation in the TCA cycle, as indicated by increased ATP-coupled mitochondrial respiration and incorporation of succinate-derived carbons into downstream TCA cycle intermediates, which also occurs in primary myeloma cells. Succinate-driven proliferation was dependent upon mitochondrial oxidative phosphorylation and abrogated by ATP synthase inhibition. Furthermore, interrogation of large-scale transcriptomic data identified that elevated expression of a mitochondrial succinate transporter associates with accelerated disease progression in myeloma, indicating this mechanism may promote plasma cell growth in vivo and highlighting a target for therapeutic intervention.

PMID:
42993627
Bibliographic data and abstract were imported from PubMed on 07 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement